Accendra Health Inc insider trading
Every open-market purchase and sale by Accendra Health Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Does following Accendra Health Inc’s insiders pay?
From February 11, 2010 to August 14, 2025, 30 insiders reported 20 open-market purchases and 97 sales not made under a pre-set plan in Accendra Health Inc. Twelve months after each purchase was reported, the shares were +21.5% against the S&P 500 on average (median −12.2%), over 20 purchases with a full year of prices; 40% beat the index. After sales, the shares moved −18.2% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 4, 2014 into $2,686 by November 2, 2026, −9.9% a year. It held shares 58% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $30,084 (+9.1% a year), and held throughout $49,901 (+13.6%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Davis Erika T | SVP, Chief Administr. Officer | 0 | — | — | 13 | −26.1% (13) | August 23, 2018 |
| Smith Craig R | Executive Chairman | 0 | — | — | 11 | −16.2% (11) | January 10, 2017 |
| Colpo Charles C | SVP, Strategic Supplier Mgmt | 0 | — | — | 10 | −32.0% (10) | August 28, 2018 |
| Henkel Robert J | Director | 9 | +32.8% (9) | 44% | 0 | — | October 18, 2022 |
| Denttartog Grace R | SVP, General Counsel | 0 | — | — | 8 | −8.3% (8) | November 10, 2015 |
| Lowry Michael Wayne | SVP, Corporate Controller | 0 | — | — | 8 | −17.6% (8) | November 12, 2020 |
| Minor G Gilmer III | Director | 0 | — | — | 8 | −6.0% (8) | February 27, 2013 |
| Van Sumeren Mark A | SVP, Strategy & Business Devel | 0 | — | — | 5 | −10.5% (5) | May 7, 2014 |
| Fogg Richard E | Director | 0 | — | — | 4 | −14.7% (4) | May 31, 2013 |
| Rogers James E | Director | 0 | — | — | 4 | −20.1% (4) | February 23, 2016 |
| Sledd Robert C | Director | 2 | +209.8% (2) | 100% | 2 | −2.8% (2) | August 11, 2020 |
| Whittemore Anne M | Director | 0 | — | — | 4 | −14.5% (4) | November 15, 2013 |
| Mears Richard W | SVP, Chief Information Officer | 0 | — | — | 3 | −22.8% (3) | February 24, 2016 |
| Moore Eddie N Jr | Director | 0 | — | — | 3 | −12.5% (3) | April 3, 2013 |
| Simpson William Marshall | SVP, Sales | 0 | — | — | 3 | −7.8% (3) | May 4, 2011 |
| Cape Olwen B | Vice President, Controller | 0 | — | — | 2 | −19.9% (2) | February 22, 2010 |
| Clarke Ev III | Exec. VP, Supply Chain | 0 | — | — | 2 | −8.8% (2) | April 29, 2011 |
| Marlatt Geoff Taylor | SVP, Manufacturer Services | 0 | — | — | 2 | −74.0% (2) | August 23, 2018 |
| Meier Richard A | EVP, Chief Financial Officer | 2 | −12.2% (2) | 0% | 0 | — | May 8, 2014 |
| Redding Peter S | Director | 0 | — | — | 2 | −9.4% (2) | November 8, 2010 |
| Bierman James L | EVP, Chief Financial Officer | 0 | — | — | 1 | −17.9% (1) | May 13, 2011 |
| Coliseum Capital Management, LLC | 10% owner | 1 | −102.3% (1) | 0% | 0 | — | April 7, 2025 |
| Coliseum Capital Partners, L.P. | 10% owner | 1 | −100.7% (1) | 0% | 0 | — | August 14, 2025 |
| Coliseum Capital, LLC | 10% owner | 1 | −86.9% (1) | 0% | 0 | — | April 10, 2025 |
| Essig Stuart | Director | 1 | +19.3% (1) | 100% | 0 | — | February 23, 2015 |
| Kordahi Rony Camil | EVP, North American Operations | 0 | — | — | 1 | −60.5% (1) | May 25, 2017 |
| Leon Jonathan A | SVP, Corporate Treasurer | 0 | — | — | 1 | +15.6% (1) | May 13, 2021 |
| Riordan Michael C | Director | 1 | +111.5% (1) | 100% | 0 | — | August 11, 2020 |
| Shackelton Christopher S | 10% owner | 1 | −92.4% (1) | 0% | 0 | — | March 4, 2025 |
| Simmons David S | Director | 1 | −9.3% (1) | 0% | 0 | — | August 27, 2015 |
When several insiders traded Accendra Health Inc
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Accendra Health Inc in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged +73.1% against the index. After 10 selling crowds, −17.9%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| April 30, 2025 | 3 buying | −16.2% | −50.7% | −78.5% |
| May 29, 2020 | 2 buying | +101.8% | +196.9% | +424.0% |
| August 31, 2018 | 3 selling | −49.8% | −68.1% | −64.6% |
| May 31, 2017 | 3 selling | −14.7% | −50.5% | −60.8% |
| March 31, 2017 | 3 selling | −9.3% | −21.8% | −66.3% |
| February 29, 2016 | 5 selling | −14.4% | −27.1% | −30.6% |
| November 28, 2014 | 4 selling | +1.6% | −4.3% | +13.2% |
| February 28, 2014 | 3 selling | −3.3% | −8.3% | −9.6% |
| November 30, 2012 | 3 selling | +4.7% | +9.0% | +13.9% |
| February 29, 2012 | 3 selling | −1.9% | −8.5% | −9.3% |
| November 30, 2010 | 3 selling | −1.2% | +8.7% | +3.4% |
| April 30, 2010 | 8 selling | −6.3% | −8.1% | −4.7% |